NZ236511A - Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions - Google Patents

Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions

Info

Publication number
NZ236511A
NZ236511A NZ236511A NZ23651190A NZ236511A NZ 236511 A NZ236511 A NZ 236511A NZ 236511 A NZ236511 A NZ 236511A NZ 23651190 A NZ23651190 A NZ 23651190A NZ 236511 A NZ236511 A NZ 236511A
Authority
NZ
New Zealand
Prior art keywords
antibodies
binding
human
subsequences
residues
Prior art date
Application number
NZ236511A
Other languages
English (en)
Inventor
Lata Ramanathan
Gail F Seelig
Paul P Trotta
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NZ236511A publication Critical patent/NZ236511A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ236511A 1989-12-20 1990-12-18 Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions NZ236511A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45357089A 1989-12-20 1989-12-20

Publications (1)

Publication Number Publication Date
NZ236511A true NZ236511A (en) 1993-02-25

Family

ID=23801108

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ236511A NZ236511A (en) 1989-12-20 1990-12-18 Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions

Country Status (26)

Country Link
US (1) US6358509B1 (cg-RX-API-DMAC7.html)
EP (1) EP0506826B1 (cg-RX-API-DMAC7.html)
JP (1) JPH0730116B2 (cg-RX-API-DMAC7.html)
KR (1) KR960016862B1 (cg-RX-API-DMAC7.html)
AT (1) ATE136906T1 (cg-RX-API-DMAC7.html)
AU (1) AU639754B2 (cg-RX-API-DMAC7.html)
CA (1) CA2071908C (cg-RX-API-DMAC7.html)
CZ (1) CZ283050B6 (cg-RX-API-DMAC7.html)
DE (1) DE69026627T2 (cg-RX-API-DMAC7.html)
DK (1) DK0506826T3 (cg-RX-API-DMAC7.html)
ES (1) ES2085983T3 (cg-RX-API-DMAC7.html)
FI (1) FI104180B (cg-RX-API-DMAC7.html)
GR (1) GR3020325T3 (cg-RX-API-DMAC7.html)
HU (1) HU215245B (cg-RX-API-DMAC7.html)
IE (1) IE74708B1 (cg-RX-API-DMAC7.html)
IL (1) IL96714A0 (cg-RX-API-DMAC7.html)
MX (1) MX9203401A (cg-RX-API-DMAC7.html)
MY (1) MY106507A (cg-RX-API-DMAC7.html)
NO (1) NO922457L (cg-RX-API-DMAC7.html)
NZ (1) NZ236511A (cg-RX-API-DMAC7.html)
OA (1) OA09704A (cg-RX-API-DMAC7.html)
PT (1) PT96230B (cg-RX-API-DMAC7.html)
SK (1) SK279933B6 (cg-RX-API-DMAC7.html)
TW (1) TW221675B (cg-RX-API-DMAC7.html)
WO (1) WO1991009059A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA9010190B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
AP583A (en) * 1993-09-07 1997-04-14 Smithkline Beecham Corp Recombination IL4 antibodies useful in treatment of IL4 mediated disorders.
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
JP2001511187A (ja) * 1997-02-28 2001-08-07 エンゾー セラピュウティクス, インコーポレイテッド 選択的免疫ダウンレギュレーション(sidr)を行う新規プロセス
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US7507706B1 (en) 1998-12-14 2009-03-24 Genetics Institute, Llc Cytokine receptor chain
EP1142961B1 (en) * 2000-04-06 2008-08-06 FUJIFILM Corporation Dye complex and optical information recording medium
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
US20020076409A1 (en) * 2000-07-12 2002-06-20 March Carl J. Method for treating cancer
US20030170258A1 (en) * 2001-05-09 2003-09-11 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (SIDR)
FR2838444B1 (fr) 2002-04-10 2016-01-01 Neovacs Nouveaux peptides et leur application en therapeutique
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
WO2004003156A2 (en) * 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
RU2382049C2 (ru) * 2004-08-03 2010-02-20 Новартис Аг ЧЕЛОВЕЧЕСКИЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА К ЧЕЛОВЕЧЕСКОМУ ИНТЕРЛЕЙКИНУ-4 (hIL-4)
AR050044A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
AU2009316076B2 (en) * 2008-11-17 2015-11-19 Kobenhavns Universitet IL-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
AR085138A1 (es) 2011-02-04 2013-09-11 Genentech Inc VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
EP2981286A4 (en) * 2013-04-05 2016-08-24 Hoffmann La Roche ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
PL3140392T3 (pl) 2014-05-06 2023-11-27 F. Hoffmann-La Roche Ag Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
WO2019148405A1 (zh) * 2018-02-01 2019-08-08 北京凯因科技股份有限公司 IL-4Rα抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
ZA872781B (en) 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
EP0327283B1 (en) * 1988-02-02 1993-08-18 Schering Biotech Corporation Method of reducing immunoglobulin e responses

Also Published As

Publication number Publication date
FI922847A0 (fi) 1992-06-18
SK635290A3 (en) 1999-06-11
HU9202073D0 (en) 1992-09-28
SK279933B6 (sk) 1999-06-11
NO922457D0 (no) 1992-06-19
MY106507A (en) 1995-06-30
DK0506826T3 (da) 1996-05-13
MX9203401A (es) 1992-07-01
TW221675B (cg-RX-API-DMAC7.html) 1994-03-11
ATE136906T1 (de) 1996-05-15
AU7176291A (en) 1991-07-18
JPH04506359A (ja) 1992-11-05
GR3020325T3 (en) 1996-09-30
PT96230A (pt) 1991-10-15
CA2071908C (en) 2002-04-30
EP0506826A1 (en) 1992-10-07
OA09704A (en) 1993-08-30
JPH0730116B2 (ja) 1995-04-05
HU215245B (hu) 1998-11-30
AU639754B2 (en) 1993-08-05
US6358509B1 (en) 2002-03-19
ZA9010190B (en) 1991-08-28
EP0506826B1 (en) 1996-04-17
IL96714A0 (en) 1991-09-16
FI104180B1 (fi) 1999-11-30
NO922457L (no) 1992-06-19
IE904589A1 (en) 1991-07-03
KR960016862B1 (ko) 1996-12-23
DE69026627D1 (de) 1996-05-23
FI922847L (fi) 1992-06-18
WO1991009059A1 (en) 1991-06-27
CZ283050B6 (cs) 1997-12-17
PT96230B (pt) 1998-06-30
DE69026627T2 (de) 1996-08-22
KR920703642A (ko) 1992-12-18
ES2085983T3 (es) 1996-06-16
CZ635290A3 (en) 1997-08-13
FI104180B (fi) 1999-11-30
HUT64568A (en) 1994-01-28
CA2071908A1 (en) 1991-06-21
IE74708B1 (en) 1997-07-30

Similar Documents

Publication Publication Date Title
TW221675B (cg-RX-API-DMAC7.html)
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
PT931092E (pt) Variantes de factor de crescimento de celulas endoteliais vasculares que possuem propriedades antagonistas
ES8607564A1 (es) Un metodo para determinar la presencia de un determinante antigenico de interleuquina-2-en una muestra.
DE68929384D1 (de) Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE69434538D1 (de) Vaskularer endothelialer wachstumsfaktor 2
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
DK0920509T3 (da) Polypeptider, der er i stand til at danne antigenbindende strukturer med specificitet for Rhesus D-antigener, DNA, der koder herfor, samt fremgangsmåde til fremstilling heraf og anvendelse heraf
TW272197B (cg-RX-API-DMAC7.html)
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
EP0992584A3 (en) Purified mammalian FLT3 ligands and agonists and antagonists thereof
ATE48142T1 (de) Blutprotein, verfahren zu seiner herstellung, antikoerper gegen dieses protein und dieses protein oder diese antikoerper enthaltende pharmazeutische zubereitungen.
Seelig Antagonists of human gamma interferon
IT8807011V0 (it) Perfezionamento degli elementi che attrezzano il recipiente, adatto per impastare farina con altri ingredienti e per la cottura dell'impasto ottenuto.